Article
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
JAMA internal medicine - 1 Jan 2016
Chahal Harinder S, Marseille Elliot A, Tice Jeffrey A, Pearson Steve D, Ollendorf Daniel A, Fox Rena K, Kahn James G
Abstract excerpt
IMPORTANCE: Novel treatments for hepatitis C virus (HCV) infection are highly efficacious but costly. Thus, many insurers cover therapy only in advanced fibrosis stages. The added health benefits and costs of early treatment are unknown. OBJECTIVE: To assess the cost-effectiveness of (1) treating all patients with HCV vs only those with advanced fibrosis and (2) treating each stage of fibrosis. DESIGN, SETTING,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.